Trials explorer

AI-generated summary

QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC is being studied. Conditions: Unresectable Colorectal Cancer, Metastatic Colorectal Cancer (CRC), MSI-H/dMMR Colorectal Cancer • Eligibility: Inclusion Criteria: * Voluntarily signs the informed consent form. * Aged between 18 and 80 years (inclusive) at the time of consent; no gender restriction. * Histologically confirmed…. Goal: This is a single-arm, multi-center, exploratory study evaluating the efficacy and safety of iparomlimab and tuvonralimab (QL1706) in combination with bevacizumab for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic colorectal cancer. Eligible participants who meet the inclusion and exclusion criteria will provide written informed consent and receive QL1706 at 5.0 mg/kg and bevacizumab at 7.5 mg/kg on Day 1 of every 3-week cycle (Q3W), until disease progression or completion of 2 years of treatment. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Qianfoshan Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer is being studied. Conditions: Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) • Eligibility: Inclusion Criteria: 1. Willing and able to provide written informed consent. 2. Histological or cytological documentation of adenocarcinoma of the colon or rectum. 3. Eastern Cooperative Oncology Group…. Goal: KEYNOTE-177 is currently the only randomized controlled phase III clinical trial evaluating the efficacy and safety of pembrolizumab versus standard chemotherapy combined with targeted first-line therapy for dMMR/MSI-H metastatic colorectal cancer. The study was conducted at 192 centers in 23 countries and enrolled a total of 307 subjects. Phase/Status/Sponsor: Unknown phase; RECRUITING; Sun Yat-sen University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer is being studied. Conditions: MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer • Eligibility: Inclusion Criteria: * Written and signed informed consent. * Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or * The estimated life expectancy of ≥3 months. *…. Goal: This is a single-arm, multicenter phase II clinical study. The aim is to evaluate the safety, tolerability, and anti-tumor activities of AK104(a PD-1/CTLA-4 bispecific antibody) in MSI-H/dMMR locally advanced gastric adenocarcinoma and colorectal cancer during the perioperative period.Eligible patients will receive AK104 for three cycles before surgery and at most 6 months after surgery. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Peking University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer is being studied. Conditions: Colorectal Carcinoma • Eligibility: Inclusion Criteria: 1. Male or female subjects aged ≥18 years 2. ECOG PS 0/1 3. Histologically proven, stage III (i.e., any T, N1 or N2, M0) adenocarcinoma of…. Goal: In this open-label phase III study, patients with local advanced colon cancer (TanyN+ ,M0, dMMR/MSI-H, at least 10cm from the anus verge)will be scheduled to Group A: receive anti-PD-1 antibody alone (8 cycles, 200mg iv drip Q3W) and Group B (4 or 8 cycles of XELOX: oxaliplatin 130mg/m2 day 1, capecitabine 2000mg/m2 days 1-14, repeated every 21 days). The primary endpoint was 3 Disease-free survival; analyses were done based on all patients with post-randomization data. Phase/Status/Sponsor: Unknown phase; RECRUITING; Sun Yat-sen University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer is being studied. Conditions: Colorectal Cancer • Eligibility: Inclusion Criteria for Cohort A and B: * Age ≥70 years. * Eastern Cooperative Oncology Group (ECOG) performance status 0 -2 * Have histologically proven localized or locally…. Goal: The purpose of this study is to evaluate the safety and clinical activity of cemiplimab and the combination of cemiplimab/fianlimab in microsatellite unstable localized or locally advanced colorectal cancer diagnosed in patients age 70 or greater or in patients age 18 or greater considered poor candidates for surgery. Phase/Status/Sponsor: Unknown phase; RECRUITING; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Combination of Temsirolimus (Torisel®) and Pegylated Liposomal Doxorubicin (PLD, Doxil®/Caelyx®) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer is being studied. Conditions: Advanced/Recurrent Breast Cancer, Endometrial Cancer, Ovarian Cancer • Eligibility: Inclusion Criteria: * Patients with proven advanced breast cancer, endometrial cancer or ovarian cancer, who are refractory to standard therapies or for whom no standard therapy exists. *…. Goal: A study to examine the combination of temsirolimus and Caelyx® (chemotherapeutic) in advanced or recurrent breast, endometrial and ovarian cancer. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Radboud University Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests S095029, an anti-NKG2A antibody, given with pembrolizumab to treat MSI-H/dMMR gastric or gastroesophageal junction adenocarcinoma that is locally advanced and unresectable or metastatic. - It has two parts: a safety lead-in to find the recommended dose, and a later expansion to assess anti-tumor activity and safety. - Eligible participants have MSI-H/dMMR-confirmed locally advanced unresectable or metastatic gastric/GEJ adenocarcinoma. - Key exclusions include more than one prior treatment in this setting, prior checkpoint inhibitor therapy, recent systemic anticancer therapy within 4 weeks, recent radiotherapy within 2 weeks, or major surgery within 4 weeks or not recovered.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer is being studied. Conditions: Colorectal Cancer, Colorectal Adenocarcinoma • Eligibility: Inclusion Criteria: * Previously treated metastatic colorectal adenocarcinoma, histologically proven. Subjects must have previously received and had evidence of progression on cetuximab, bevacizumab, 5FU, irinotecan, and oxaliplatin, or…. Goal: In this study, the investigational drug, temsirolimus, will be combined with cetuximab, a biologic agent used in the treatment of colorectal cancer. Cetuximab in combination with temsirolimus may be more effective in treating advanced colorectal cancer than cetuximab alone. Phase/Status/Sponsor: Unknown phase; COMPLETED; Jeffrey W. Clark, MD.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma is being studied. Conditions: Melanoma, Recurrent Melanoma, Stage III Melanoma +1 • Eligibility: Inclusion Criteria: * Histologically or cytologically confirmed melanoma, meeting 1 of the following criteria: recurrent or unresectable stage III disease, stage IV disease, non-choroidal origin. * Tumor must…. Goal: This phase II portion of the trial is studying the side effects and best dose of temsirolimus when given together with sorafenib and to see how well they work in treating patients with metastatic, recurrent, or unresectable melanoma. Sorafenib and temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; WITHDRAWN; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Beta-only IL-2 ImmunoTherapY Study is being studied. Conditions: Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma +34 • Eligibility: Key Inclusion Criteria: 1. Aged at least 18 years (inclusive at the time of informed consent). 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.…. Goal: This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Medicenna Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors is being studied. Conditions: Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer +6 • Eligibility: Inclusion Criteria: 1. Adult participants must be 18 years of age or older 2. Advanced or metastatic solid tumors excluding primary central nervous system (CNS) tumors 3. For…. Goal: The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab. Phase/Status/Sponsor: Unknown phase; RECRUITING; IDEAYA Biosciences.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors is being studied. Conditions: Brain and Central Nervous System Tumors, Metastatic Cancer • Eligibility: Inclusion Criteria Patients must be at least 18 years of age. Patients must have either a primary or metastatic brain tumor(s). Patients must be in need of a…. Goal: RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about how this treatment is used by the body. Phase/Status/Sponsor: Unknown phase; COMPLETED; City of Hope Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations is being studied. Conditions: Metastatic Colorectal Cancer • Eligibility: Inclusion Criteria: * Histologically verified colorectal adenocarcinomas * Age \> 18 years and \< 70 * Metastatic colorectal cancer refractory 5-FU, oxaliplatin and irinotecan containing treatment regimes *…. Goal: The purpose of this study is to investigate the safety and efficacy of temsirolimus as a single drug, and of temsirolimus in combination with irinotecan in chemotherapy resistant patients with KRAS mutated colorectal cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; Vejle Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma is being studied. Conditions: Melanoma, Recurrent Melanoma, Stage III Melanoma +1 • Eligibility: Criteria: * Histologically or cytologically confirmed melanoma, meeting 1 of the following criteria: recurrent or unresectable stage III disease, stage IV disease, non-choroidal origin. * Tumor must be…. Goal: This phase I trial is studying the side effects and best dose of temsirolimus when given together with sorafenib and to see how well they work in treating patients with metastatic, recurrent, or unresectable melanoma. Sorafenib and temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors is being studied. Conditions: MSI-H Colorectal Cancer, Melanoma, Anal Carcinoma +28 • Eligibility: Inclusion Criteria: 1. Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of PD1 mRNA high-expression…. Goal: This is an open-label, parallel group, non-randomized, multicenter phase II study to evaluate the efficacy of spartalizumab (cohorts 1 and 2) and tislelizumab (cohort 3) in monotherapy in patients with PD1-high-expressing tumors. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; SOLTI Breast Cancer Research Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan) is being studied. Conditions: Renal Cell Carcinoma • Eligibility: Inclusion Criteria: * Patients treated with Torisel (patients with metastatic and/or radically unresectable or advanced renal cell carcinoma). Exclusion Criteria: * Patients not administered Torisel. * Patients with…. Goal: The objective of this investigation is to determine the following items in all patients receiving Torisel for a certain period after marketing: 1. Confirmation of efficacy and safety for medical practice use. Phase/Status/Sponsor: Unknown phase; COMPLETED; Pfizer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Combination Immunotherapy in Rare Cancers Under InvesTigation is being studied. Conditions: Advanced Biliary Tract Cancer, Neuroendocrine Tumors, Female Reproductive System Neoplasm +1 • Eligibility: Inclusion Criteria: 1. Signed Written Informed Consent * Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the…. Goal: The four tumour streams that will be studied in this protocol are based on immunotherapy sensitive rare cancers from CA209-538 which will be further investigated under this protocol and divided into four groups: 1. Neuroendocrine cancers: Atypical bronchial carcinoid, neuroendocrine carcinoma and Grade 3 NETs independent of primary site (SCLC excluded) 2. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Olivia Newton-John Cancer Research Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies is being studied. Conditions: Resistant Solid Malignancies • Eligibility: Inclusion and Exclusion Criteria: * Patients must have a histologically or cytologically proven solid malignancy which is resistant to conventional therapy or for which no effective therapy is…. Goal: Rationale: The Mammalian Target of Rapamycin (mTOR) is a large polypeptide serine/threonine kinase of 289 kDa; kinases have been shown to be important regulators of cancer cell cycle, proliferation, invasion, and angiogenesis, and mTOR has been shown to have a key role in the signaling of malignant cell growth, proliferation, differentiation, migration, and survival. Inhibition of mTOR would result in arrest of cell growth in the G1 phase of the cell cycle. Phase/Status/Sponsor: Unknown phase; COMPLETED; Washington University School of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive is being studied. Conditions: Advanced Solid Tumor • Eligibility: Inclusion Criteria: * Immunotherapy naive and without access to approved and/or available immune checkpoint inhibitor (ICI) therapy. * Measurable disease per RECIST v1.1. * One of the following…. Goal: This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Incyte Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests adding PDS01ADC to a liver-directed chemotherapy approach (HAIP with FUDR and dexamethasone) plus standard systemic chemotherapy for certain liver cancers. It is for adults 18 and older with unresectable cancer confined to or dominant in the liver, specifically metastatic colorectal cancer to the liver, intrahepatic cholangiocarcinoma, or adrenocortical carcinoma with liver metastases. The study aims to learn the objective response rate, i.e., how often tumors shrink, with this combination therapy. Eligible participants must have had first-line systemic chemotherapy and will receive HAIP-delivered chemotherapy, PDS01ADC injections every four weeks, and ongoing systemic chemotherapy. Exclusions include active autoimmune disease (with some steroid replacement exceptions), active hepatitis B or C infection, significant cardiovascular disease, prior FUDR exposure, and other factors that could confound results.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests nanvuranlat in adults with biliary tract cancer to find a recommended dose regimen (Part A) and to study its effect on overall survival compared with the physician’s best choice (Part B). Participants are 18 years or older with advanced, metastatic, or unresectable BTC who have received one prior platinum-based therapy. Treatments are given every two weeks with safety checks, tumor imaging, and exploratory tests to understand how the drug works. Key exclusions include active CNS metastases, significant cardiovascular disease, HIV not on therapy, active HBV or HCV infection, and pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma is being studied. Conditions: Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma +6 • Eligibility: Inclusion Criteria: * Patients with measurable or non-measurable (detectable) recurrent endometrial cancer * Measurable disease will be defined and monitored by RECIST v 1.1. Measurable disease is defined…. Goal: This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after a period of time during which the cancer could not be detected (recurrent). Deoxyribonucleic acid (DNA) mismatch repair (MMR) is a system for recognizing and repairing damaged DNA. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests BOLD-100 given with the chemotherapy FOLFOX in adults with advanced gastrointestinal cancers (such as colorectal, pancreatic, gastric cancers, and cholangiocarcinoma) to assess safety and tolerability, using a dose-escalation phase followed by expansion. - In the colorectal cancer arm (Arm VII), eligible patients who are oxaliplatin-naïve and have had only one prior metastatic therapy will be randomized to three groups: BOLD-100 at 500 mg/m2 with FOLFOX, BOLD-100 at 625 mg/m2 with FOLFOX, or FOLFOX alone, with quality-of-life assessments. - The trial aims to learn whether adding BOLD-100 provides anti-tumor activity and how it affects patients’ quality of life, while establishing safe dose levels. - Key exclusions include neuropathy greater than grade 2, CNS metastases, active HIV on ART, DPD deficiency, prior exposure to BOLD-100 (for Arm VII), MSI-H tumors, and recent major treatments or other serious conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial is testing the safety of dostarlimab in Indian adults with recurrent or advanced endometrial cancer that has progressed after platinum-based therapy. It aims to learn how safe dostarlimab is for people whose tumors are dMMR/MSI-H and who are eligible to receive the drug. Participants must be 18 or older, able to give consent, have a negative pregnancy test, and use contraception if needed; several health-related exclusions apply. The study is not yet recruiting, and GlaxoSmithKline is the sponsor.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Dietary Fiber and Probiotics in Advanced Colorectal Cancer is being studied. Conditions: Colorectal Cancer (MSI-H), Malnutrition (Calorie) • Eligibility: Inclusion Criteria: * Pathologically confirmed diagnosis of stage II-IV colorectal cancer post-resection. * Receiving active adjuvant chemotherapy. * Documented moderate-to-severe malnutrition (PG-SGA score ≥ 4). * Ability to…. Goal: This single-center, prospective, randomized controlled trial was conducted to evaluate the efficacy of a 12-week combined dietary fiber and probiotic supplementation on gut microbiota, immune function, nutritional status, and survival outcomes in malnourished patients with advanced colorectal cancer undergoing conventional therapy, compared to standard nutritional support alone. Phase/Status/Sponsor: Unknown phase; COMPLETED; The First Hospital of Hebei Medical University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) is being studied. Conditions: Colorectal Neoplasms • Eligibility: The main inclusion and exclusion criteria include but are not limited to the following: Inclusion Criteria: Inclusion Criteria include, but are not limited to: * Has a histologically…. Goal: In this study, Chinese participants with MSI-H or dMMR advanced colorectal cancer will be assigned to receive either pembrolizumab or the Investigator's choice of 1 of 6 standard of care (SOC) chemotherapy regimens for treatment. There is no hypothesis testing for this study. Phase/Status/Sponsor: Unknown phase; RECRUITING; Merck Sharp & Dohme LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies is being studied. Conditions: Gastric Cancer, Esophageal Adenocarcinoma, Hepatocellular Carcinoma +1 • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years 2. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 3. Histologically confirmed diagnosis of any of the following: • Gastric or…. Goal: The investigators propose to evaluate the safety of drug combinations in patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies. Finding effective novel therapies for patients with advanced gastric cancer and other GI malignancies is an area of great unmet need. Phase/Status/Sponsor: Unknown phase; RECRUITING; Anwaar Saeed.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer is being studied. Conditions: Metastatic Colon Cancer, Stage III Colon Cancer • Eligibility: Inclusion Criteria: * Participants must have histologically confirmed resected Stage III adenocarcinoma of the colon. Any T \[Tx, T1, T2, T3, or T4-\], N1-2M0. * Participants must have…. Goal: This research study is comparing two standard of care treatment options based on blood test results for participants who have metastatic colon cancer. The names of the potential treatments involved in this study are: * Active surveillance * FOLFIRI treatment * Nivolumab treatment * Encorafenib/Binimetinib/Cetuximab treatment * Trastuzumab + Pertuzumab Phase/Status/Sponsor: Unknown phase; RECRUITING; Massachusetts General Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests adding lenvatinib to nivolumab plus chemotherapy for gastric cancer with peritoneal metastasis and malignant ascites. - It is for adults with newly diagnosed or recurrent/metastatic gastric or GEJ adenocarcinoma who have peritoneal metastasis with grade ≥2 ascites and a PD-L1 CPS ≥5. - The study aims to learn about the safety and efficacy of this combination and whether it can improve outcomes, such as survival, in this group. - Key exclusions include uncontrolled illness or infection, pregnancy or breastfeeding, HIV or active hepatitis B/C infection, recent major surgery, and other concurrent cancer therapies.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests amivantamab plus FOLFIRI versus cetuximab/bevacizumab plus FOLFIRI in people with KRAS/NRAS and BRAF wild-type colorectal cancer who have previously received chemotherapy. - It aims to learn whether the amivantamab combination improves progression-free survival and overall survival compared with the cetuximab/bevacizumab combination. - Eligible participants have recurrent, unresectable, or metastatic colorectal cancer with confirmed KRAS/NRAS and BRAF wild-type status, have had at least one prior systemic therapy for metastatic disease, and have ECOG 0–1. - Key exclusions include preexisting interstitial lung disease/pneumonitis, allergies to study drugs, prior exposure to irinotecan or EGFR/MET inhibitors, HER2-positive tumors, or another active malignancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry is being studied. Conditions: Cancer, Metastatic, Cancer, Cancer of Pancreas +40 • Eligibility: Inclusion Criteria: * Pts with solid and hematological malignancies; * Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2,…. Goal: International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention. Phase/Status/Sponsor: Unknown phase; RECRUITING; Massive Bio, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer is being studied. Conditions: BRAF V600 Colorectal Cancer • Eligibility: Inclusion Criteria: * Age ≥18 years and ≤75 years * Histologically confirmed metastatic colorectal adenocarcinoma * BRAF V600E mutation confirmed by tissue pathology or ctDNA testing (PCR or…. Goal: The goal of this clinical trial is to learn if Iparomlimab and Tuvonralimab combined with bevacizumab and FOLFIRI (IB-FOLFIRI) is safe and effective in treating adults with BRAF V600E-mutant metastatic colorectal cancer (mCRC). The main questions it aims to answer are: Does IB-FOLFIRI improve clinical outcomes compared with historical outcomes in this population? Phase/Status/Sponsor: Unknown phase; RECRUITING; Sun Yat-sen University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors is being studied. Conditions: Solid Tumors, Gastric Cancer, Esophagogastric Juction Cancer +1 • Eligibility: Inclusion Criteria Patients who meet ALL the following inclusion criteria will be eligible to participate in the study: 1. ≥18 years of age. 2. Histologically confirmed, locally advanced,…. Goal: The goal of this clinical trial is to learn if the investigational drug (JR8603) is safe and effective in treating patients with solid tumors after their initial rounds of treatment with other drugs did not work. Phase/Status/Sponsor: Unknown phase; RECRUITING; JiaRay Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study on the Safety and Efficacy of MR-Linac Technique in Patients With Unresectable Locally Advanced Colon Cancer is being studied. Conditions: Safety and Efficacy • Eligibility: Inclusion criteria: 1. Patients over 18 years old 2. Patients can remain in a stationary position on the treatment bed for 1-1.5 hours 3. ECOG score 0-1 4.…. Goal: In this phase I single-arm clinical study, 20 patients with T4 unresectable locally advanced colon cancer are proposed to be enrolled, who will be treated with MR-Linac with short course radiotherapy (25Gy/5F), followed by 4 cycles of mFOLFOX6 or 3 cycles of XELOX chemotherapy, then radical surgical resection, and then postoperatively with 8 cycles of mFOLFOX6 or 5 cycles of XELOX. The study will assess patients' surgical R0 resection rate, pCR or cCR rate, PFS, OS, and related adverse effects of treatment, aiming to explore the feasibility, safety, and efficacy of MR-Linac in the treatment of unresectable locally advanced colon cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; Sichuan Cancer Hospital and Research Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study is testing a combination of pembrolizumab and lenvatinib for people with anaplastic thyroid cancer. It is recruiting adults in Russia whose cancer cannot be fully removed by surgery and who have a reasonably good performance status. The trial aims to find out whether this drug combination can effectively treat the cancer and how safe it is, with responses measured using iRECIST criteria. Key exclusions include BRAF V600 mutations without prior targeted therapy, significant bleeding risk or invasion into large vessels, pregnancy, and poor functional status.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tests zanzalintinib in combination with paclitaxel to find the best dose for the next phase in people with recurrent high-grade uterine cancer. It also aims to assess safety and tolerability and to learn how often tumors respond to the treatment. Eligible participants are adults with recurrent high-grade uterine cancer (including endometrioid, serous, mixed high-grade, or uterine carcinosarcoma) who progressed on or could not tolerate platinum therapy, with 1–2 prior cancer treatments and measurable disease. Key exclusions include prior exposure to zanzalintinib, known brain metastases unless adequately treated and stable, recent use of certain therapies, QT prolongation, pregnancy, and other conditions that could make participation unsafe.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors is being studied. Conditions: Solid Tumor • Eligibility: Inclusion Criteria: 1. Must be ≥ 18 years of age when signing informed consent. 2. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 without deterioration in…. Goal: This is a phase Ib/II, open, dose-escalation and expansion study of an anti-PD1/TIM3 bispecific antibody，LB1410 in combination with an anti-Claudin18.2/IL-10 fusion protein, LB4330 in patients with advanced or metastatic solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; L & L Bio Co., Ltd., Ningbo, China.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This clinical trial is testing intravenous HNF4α srRNA in adults with locally unresectable or metastatic colorectal cancer to evaluate safety and tolerability and to gather early clues about its effectiveness. - It is a single-arm, open-label, first-in-human dose-escalation study with three dose levels (25 μg, 50 μg, 100 μg) given initially, with a second treatment about 14 ± 3 days later and subsequent cycles roughly every 28 ± 7 days; the investigators may add immunotherapy after review of safety and prior results. - Eligible participants include adults with histologically confirmed CRC that cannot be removed surgically or has metastasized and who have progressed on or cannot tolerate standard therapies, including those with dMMR/MSI-H tumors and measurable disease. - Key exclusions noted are brain metastases, significant liver or kidney dysfunction, uncontrolled infections or autoimmune disease, recent cancer treatments, pregnancy or lactation, and infection with HIV or active HBV/HCV.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients is being studied. Conditions: Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer • Eligibility: Inclusion: 1. Age ≥18 years on day of signing informed consent. 2. Specific by tumor cohorts: a. For the HSNCC cohort, histologically confirmed diagnosis of advanced and/or metastatic…. Goal: This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. Phase/Status/Sponsor: Unknown phase; RECRUITING; Vyriad, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Skin Tumor Biomarkers by Mass Spectrometry Imaging is being studied. Conditions: Skin Cancer, Squamous Cell Carcinoma, Basal Cell Carcinoma +1 • Eligibility: Inclusion Criteria: * Patients above 18 years of age. * Patients presenting with AKs, SCCs and BCCs. * Written informed consent obtained from patient. Exclusion Criteria: • Immunosuppressed…. Goal: The purpose of the study is to investigate the ability of mass spectrometry imaging to locate aggregates of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) ex-vivo, and to distinguish areas containing these carcinomas from normal skin. It is suggested that non-melanoma skin cancer (NMSC) cells show a different profile of endogenous lipids than healthe skin tissue which can be used as identifying biomarkers. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Bispebjerg Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

How Epigenetic Changes in hMLH1 Connect Lab Research With Diagnosis in Gastric Cancer is being studied. Conditions: Gastrectomy for Gastric Cancer, Gastrectomy, MLH1 Gene Mutation +1 • Eligibility: Inclusion Criteria: * Patients who underwent elective gastrectomy for Stage I-IV gastric cancer. * Surgery performed at the General Surgery Unit of Fondazione Policlinico Universitario A. Gemelli IRCCS.…. Goal: DNA methylation is one of the key mechanisms that are thought to underlie the association between aging and cancer. Several methylation-based measures of biological aging have been developed and have demonstrated an association with mortality and, in some cases, with cancer incidence. Phase/Status/Sponsor: Unknown phase; RECRUITING; Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Exploration of the Dynamic Changes and Mechanisms of the Immune Microenvironment in Advanced Colorectal Cancer Treated With IBI363 Combination Therapy is being studied. Conditions: Immunotherapy • Eligibility: Inclusion Criteria: 1. The participant must sign a written informed consent form (ICF) and be able to comply with the protocol-specified visit schedule and related procedures. 2. Age…. Goal: Colorectal cancer (CRC) ranks as the fifth most common malignant tumor in the Chinese population. In current clinical practice, standard first- and second-line treatments for metastatic microsatellite-stable (MSS)/proficient mismatch repair (pMMR) CRC are based on multi-drug combination chemotherapy regimens combined with targeted therapies. Phase/Status/Sponsor: Unknown phase; RECRUITING; jianming xu.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer is being studied. Conditions: Colorectal Cancer Metastatic, Microsatellite Stable Colorectal Carcinoma, Refractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer • Eligibility: Inclusion Criteria: * Be willing and able to provide written informed consent. * Histologically confirmed pMMR or MSS mCRC * Male or female, aged ≥ 18 years *…. Goal: Single-arm, open-label, multicenter phase 2 clinical trial evaluating the clinical and the immunological activity of an innovative strategy with an induction combo immunotherapy (Pembrolizumab plus DC Vaccine) followed by a maintenance chemotherapy (FTD/TPI plus Bevacizumab) in patients with refractory MSS/pMMR metastatic colorectal cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: \- I. Males ≥ 18 years of age II. Histologically confirmed adenocarcinoma of the prostate without pathologic evidence of small cell differentiation at the time of…. Goal: The objective of this study is to see if providing an appropriate therapy based on the genomic testing of prostate tumour tissue will result in an improved clinical response. Each participant will be treated with 8 weeks of a luteinizing hormone-releasing hormone agonist (LHRHa) plus apalutamide (APA) while genome sequence characterization is being done. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of British Columbia.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Camrelizumab Combined With Neoadjuvant Chemotherapy After Stent Placement for Left-Sided Obstructive Colonic Cancer is being studied. Conditions: Colorectal Cancer, Neoadjuvant Chemotherapy, Stent +2 • Eligibility: Inclusion Criteria: * Radiologically proven colonic obstruction of the left colon/upper rectum presumed secondary to a carcinoma * Able to give written, informed consent * Primary tumor was…. Goal: Patients with obstruction are associated with worse oncologic outcomes compared with those having nonobstructive tumors. Conventionally, patients with malignant large bowel obstruction receive emergency surgery, with morbidity rates of 30%-60% and mortality rates of 7-22%, and about two-thirds of such patients end up with a permanent stoma. Phase/Status/Sponsor: Unknown phase; RECRUITING; Beijing Chao Yang Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer is being studied. Conditions: Unresectable Metastatic Colorectal Cancer • Eligibility: Key Inclusion Criteria: 1. Histologically proven metastatic adenocarcinoma of the colon or rectum. 1. Confirmed metastatic unresectable adenocarcinoma of the colon or the rectum. 2. Confirmed non-microsatellite instability…. Goal: The purpose of the CYAD-101-002 study is to assess the safety and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered concurrently with FOLFOX chemotherapy, followed by pembrolizumab treatment. Phase/Status/Sponsor: Unknown phase; RECRUITING; Celyad Oncology SA.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests a drug called MGC028 in adults whose ADAM9-expressing solid tumors are relapsed or refractory, unresectable, locally advanced, or metastatic. - It uses dose escalation to find a safe dose and to describe safety and side effects, including any dose-limiting toxicities and the highest dose that can be given safely. - The trial also aims to learn whether MGC028 can shrink tumors, keep cancer from growing, or control disease in these advanced cancers. - Cancers eligible for participation include NSCLC adenocarcinoma, cholangiocarcinoma, colorectal cancer, and pancreatic cancer with specific prior-treatment criteria; key exclusions include active brain metastases, prior ADAM9-targeted therapy, recent major cancer treatment, organ transplant, infection, and pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET) is being studied. Conditions: Locally Advanced Rectal Cancer (LARC), Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (mCRC) +1 • Eligibility: Inclusion Criteria: * Clinical diagnosis of gastric cancer and colorectal cancer * Aged 18 to 75 years: * Able to sign a written informed consent form and understand…. Goal: This study is a prospective, multi-cohort clinical trial designed to evaluate the preliminary efficacy and safety of zanidatamab in combination with tislelizumab and chemotherapy/radiotherapy for patients with HER2-positive locally advanced or metastatic gastrointestinal tumors. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Tao Zhang.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors is being studied. Conditions: Solid Tumor, Renal Cell Cancer Metastatic, Non-Small Cell Lung Cancer +2 • Eligibility: Key Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of metastatic or locally advanced solid tumors for which no standard therapy exists or standard therapy has failed because…. Goal: Phase 1 (Dose Escalation) of this study will assess the safety, tolerability, dose-limiting toxicity (DLT), and will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of EU101 in participants with advanced solid tumors. Phase 2 (Dose Expansion) of the study will assess the antitumor effect of EU101 in two indications including colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). Phase/Status/Sponsor: Unknown phase; RECRUITING; Eutilex.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors is being studied. Conditions: Melanoma, Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (RCC) +3 • Eligibility: Inclusion Criteria: * Prior systemic therapy, diagnoses and disease setting as follows: * For Part 1 (dose escalation), and no history of treatment with anti-CTLA-4 or anti-PD-(L)1 therapy…. Goal: The purpose of this study is to characterize the safety, tolerability, PK, and efficacy of INCB 99280 in combination with ipilimumab in participants with select solid tumors. Phase/Status/Sponsor: Unknown phase; TERMINATED; Incyte Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a Phase III, open-label, multicentre, randomized trial comparing dostarlimab with carboplatin-paclitaxel as first-line treatment for adults with MMR-deficient (MMRd/MSI-H) endometrial cancer that is recurrent or advanced. It is for women aged 18 and older with MMRd/MSI-H endometrial cancer who have measurable disease and ECOG 0-1. Randomization is 1:1 and stratified by prior adjuvant chemotherapy, prior pelvic radiotherapy, and whether the disease is newly diagnosed advanced/metastatic or relapse. Exclusion criteria include prior anti-PD-1/PD-L1 therapy, active brain metastases, certain active infections or autoimmune disease, and recent systemic anticancer therapy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tests whether adding serplulimab to FLOT chemotherapy improves the rate of complete tumor disappearance (pCR) in adults with stage III gastric adenocarcinoma. It compares serplulimab plus FLOT versus FLOT alone in a randomized design, for patients whose tumors are PD-L1 positive (CPS ≥ 1). Participants receive treatment every two weeks, have imaging at 4 and 8 weeks, then undergo surgery and may receive postoperative serplulimab with adjuvant chemotherapy or adjuvant chemotherapy alone. Key exclusions include HER2-positive tumors, MSI-H/dMMR, autoimmune disease, prior gastric cancer treatment, active infection or pregnancy. Status: ACTIVE_NOT_RECRUITING (the trial is active but not recruiting).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tests VG161, injected directly into tumors, as a standalone treatment or in combination with Nivolumab for adults with hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC). It starts with a safety run-in and then includes monotherapy groups for HCC and ICC to assess safety and anti-tumor activity. There is also a group combining VG161 with IV Nivolumab to evaluate potential added benefit. The study uses predefined stopping rules to learn whether the treatment provides meaningful responses or progression-free survival, and to decide if the trial should continue. Eligible participants are adults 18+, ECOG 0–1, with measurable injectable disease and adequate liver function; key exclusions include active infections, certain brain metastases, recent major surgery, and use of systemic immunosuppressants or anticoagulants.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests Serplulimab added to Docetaxel plus S-1, compared with Docetaxel plus S-1 alone, as adjuvant therapy after surgery for stage IIIc gastric cancer. It aims to learn whether the combination improves effectiveness and safety, including overall survival and adverse events. Eligible participants are adults 18–75 with pathology-confirmed stage IIIc gastric cancer (ECOG 0–1) whose tumors are PD-L1+ (CPS ≥5) or MSI-H or EBV+/dMMR and who have not had prior anti-tumor treatment. The trial is currently recruiting, sponsored by RenJi Hospital, and excludes pregnancy or breastfeeding, distant metastasis, prior cancer treatments, active autoimmune disease, HIV/HBV/HCV infection, and other serious health issues.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Predictive Value of PREMM5, MMRpredict, and Universal Tumor Screening for Lynch Syndrome in Vietnam is being studied. Conditions: Lynch Syndrome, Colorectal Cancer (CRC) • Eligibility: Inclusion Criteria: * Aged 18 to 70 years * Provide informed consent to participate in the study * Undergo colonoscopy with endoscopic findings suspicious for CRC * Have…. Goal: This study evaluates the predictive value of PREMM5, MMRpredict models, and Universal Tumor Screening in detecting Lynch Syndrome in colorectal cancer (CRC) patients in Vietnam. Vietnamese CRC patients (18-70 years) undergoing colonoscopy will be enrolled. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; University of Medicine and Pharmacy at Ho Chi Minh City.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients. is being studied. Conditions: CRC • Eligibility: Inclusion Criteria: * Males or females, aged ≥ 18 years. * Participants with pathologically confirmed advanced Colorectal Cancer. * Participants have at least 1 target lesion other than…. Goal: This is a multicenter, open-label Phase Ib/II clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of the HS-20110 combination therapies in Patients with Advanced Colorectal Cancer. "Rolling 6" design would be used to conduct dose escalation part of this study. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Hansoh BioMedical R&D Company.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) is being studied. Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm +3 • Eligibility: Inclusion Criteria: * Patients must have met applicable eligibility criteria in the Master MATCH Protocol prior to registration to treatment subprotocol * Patients must have an electrocardiogram (ECG)…. Goal: This phase II MATCH treatment trial identifies the effects of GSK2636771 in patients whose cancer has a genetic change called PTEN mutation or deletion. GSK2636771 may block a protein called PI3K-beta, which may be needed for growth of cancer cells that express PTEN mutations. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

GYNORYLAQ-VLINIVAL is an early-phase, non-randomized, single-arm trial enrolling by invitation to test a personalized neoantigen vaccine for people with high-risk or recurrent endometrial cancer. The vaccine, called GYNORYLAQ-TM, is selected for each patient by the GYNORYLAQ-EC platform and given with individualized background cancer therapies chosen by the treating oncologist; the vaccine itself is investigational. The study aims to evaluate safety and tolerability and to assess the feasibility of manufacturing GMP-grade, patient-specific vaccine panels. Secondary goals include measuring vaccine-induced T-cell immune responses and exploring how the platform’s quantum/physics scores relate to clinical and immunologic outcomes. Eligibility requires confirmed high-risk or recurrent endometrial cancer with measurable disease; key exclusions include active uncontrolled infection, autoimmune disease requiring systemic immunosuppression, untreated CNS metastases, and pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I) is being studied. Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm +3 • Eligibility: Inclusion Criteria: * Patients must have met applicable eligibility criteria in the Master MATCH Protocol prior to registration to treatment subprotocol * Patients must have a PIK3CA mutation…. Goal: This phase II MATCH treatment trial identifies the effects of GDC-0032 (taselisib) in patients whose cancer has a genetic change called PIK3CA mutation. Taselisib may stop the growth of cancer cells by blocking PIK3CA, a protein that may be needed for cell growth. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests two regimens for metastatic renal cell cancer that has progressed after a PD-1/PD-L1 inhibitor: lenvatinib with everolimus versus cabozantinib alone. It aims to learn which treatment works better, how safe it is, and its impact on quality of life and overall survival. Participants are adults with 1–2 prior systemic therapies for metastatic RCC and measurable disease, randomized to one of the two options. Exclusions include prior use of any of the study drugs (lenvatinib, cabozantinib, or everolimus) and certain health conditions, such as uncontrolled hypertension, active infections, untreated brain metastases, or pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests treatments for Ewing sarcoma family tumors (ESFT) and desmoplastic small round cell tumor (DSRCT) in children and young people. - Participants are split into Group A (standard-risk ESFT under 14, non-pelvic, no metastasis) who get standard chemotherapy with planned local control, and Group B (higher-risk ESFT or DSRCT, including those 14 or older or with pelvic or metastatic disease) who receive a window therapy with temsirolimus, temozolomide, and irinotecan, followed by induction chemotherapy and maintenance. - The study aims to estimate the initial response rate to the Group B window therapy and to measure overall survival, progression-free survival, time to progression, and local control outcomes. - Key exclusions include pregnancy or breastfeeding and a history of another cancer (except certain non-melanoma skin cancers); participants must not have had prior chemotherapy or radiation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is an open-label, single-arm phase II trial testing perioperative therapy that combines pembrolizumab, trastuzumab, and FLOT before surgery, then pembrolizumab plus trastuzumab after surgery for up to one year. It is for adults with HER2-positive localized esophagogastric adenocarcinoma that is potentially curable by surgery and has no distant metastasis. The study mainly aims to see if this treatment improves disease-free survival and increases the rate of pathological complete response (pCR) after surgery, compared with historical outcomes. Eligibility excludes metastatic disease, prior anti-PD-1/PD-L1 therapy, major heart problems, active infections or autoimmune disease, pregnancy, or other serious health risks.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests a patient-specific neoantigen vaccine (GRT-C901 followed by GRT-R902) given with immune checkpoint blockers and standard fluoropyrimidine/bevacizumab chemotherapy for metastatic colorectal cancer. - In Phase 2, it compares this vaccine-plus-immunotherapy approach to fluoropyrimidine/bevacizumab alone to see if it produces a molecular response measured by circulating tumor DNA. - In Phase 3, the trial aims to show clinical benefit by improving progression-free survival. - It is for adults with metastatic colorectal cancer who are planned for or recently treated with first-line regimens and have measurable disease and adequate organ function. - Key exclusions include dMMR/MSI-H tumors, BRAFV600E mutations, immune suppression or autoimmune disease, active CNS metastases, active infection or HIV/hepatitis, recent other cancer, and pregnancy; the study is currently active but not recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors is being studied. Conditions: Cancer, Melanoma, Ovary Cancer +2 • Eligibility: Subjects must fulfill all the following inclusion criteria relevant to their tumor type to be eligible for participation in the study: Inclusion Criteria Malignant Melanoma * Histopathologically confirmed…. Goal: First-in Human study evaluating the safety, tolerability and efficacy of ENB003 in combination with Pembrolizumab in solid tumors. The study is separated into two parts. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; ENB Therapeutics, Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Search of Protein Biomarkers in Order to Achieve a Molecular Classification of Gliomas is being studied. Conditions: Glioblastoma • Eligibility: Main inclusion criteria: * Patients with grade III or IV glioma newly diagnosed with histological evidence * Surgical indication * Tumor tissue available at biobank of Lille *…. Goal: The aim is to classify high grade glioma by matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI MSI). In order to provide more specific informations for the diagnosis and the prognosis of high grade glioma. Phase/Status/Sponsor: Unknown phase; COMPLETED; University Hospital, Lille.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This is a randomized trial testing cabozantinib s-malate plus nivolumab versus nivolumab alone in adults with advanced, recurrent, or metastatic endometrial cancer that has progressed after platinum-based therapy. - The study aims to learn whether the combination can improve progression-free survival and overall response rate, and to look at overall survival and safety. - It will also examine biomarkers such as PD-L1, T-cell infiltrates, and MSI/MMR status to see how they relate to outcomes. - Key exclusions include untreated or uncontrolled brain metastases (with some allowed if previously treated and controlled), prior cabozantinib, active infections or significant cardiovascular issues, pregnancy or breastfeeding, and the requirement for a baseline biopsy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer is being studied. Conditions: Metastatic Colorectal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Colorectal Cancer AJCC v7 +3 • Eligibility: Inclusion Criteria: * Patients must have histologically or cytologically confirmed non-small cell lung cancer (cohort 1) or colorectal cancer (cohort 2) * Patients must have measurable disease, defined…. Goal: This randomized phase II trial studies the side effects of durvalumab and tremelimumab and to see how well they work with or without high or low-dose radiation therapy in treating patients with colorectal or non-small cell lung cancer that has spread to other parts of the body (metastatic). Immunotherapy with durvalumab and tremelimumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

MRD-positive Colorectal Cancer Patients Combined With Personalized Immune Regulation Diagnosis is being studied. Conditions: Colorectal Cancer • Eligibility: Inclusion Criteria: 1. They must give informed consent, indicating that they understand the purpose of the study and the procedures required, and are willing to participate in the…. Goal: Establish the clinical technology system of routine adjuvant therapy combined with personalized immune regulation diagnosis and treatment technology for postoperative anti-relapse adjuvant therapy: Patients with MRD positive and high risk of recurrence after colorectal cancer surgery were enrolled. Surgical tumor tissue and blood samples were collected, tumor tissue samples were sequenced, neoantigens were analyzed, personalized immunomodulators were prepared, and routine adjuvant therapy combined with personalized immunomodulatory diagnosis and treatment technology were performed to prevent postoperative recurrence. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Second Affiliated Hospital of Wenzhou Medical University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests dostarlimab with carboplatin and paclitaxel, followed by dostarlimab alone, in Japanese participants with primary advanced or recurrent endometrial cancer. - It aims to learn how well this treatment works and how safe it is for people with endometrial cancer, including tumors that are dMMR/MSI-H or MMRp/MSS. - Eligible participants have Stage III or IV disease or first recurrence with limited curability and at least one measurable lesion, plus good performance status. - Key exclusions include having another active cancer or recent cancer treatment, uncontrolled liver or lung disease, uncontrolled brain metastases, immune system problems, prior immune checkpoint inhibitor therapy, pregnancy, HIV or hepatitis B/C infection, recent anticancer therapy, or a contraindication to carboplatin or paclitaxel.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors is being studied. Conditions: Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma +2 • Eligibility: Inclusion Criteria: * Cytologically or histologically confirmed solid tumor that is inoperable locally advanced, metastatic, or recurrent. * Dose-escalation (single-agent and combination therapy): Subjects with a solid tumor…. Goal: This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination with atezolizumab, and in combination with avelumab to subjects with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Exelixis.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tested INCB099280 to see if it is safe and tolerable, how the drug behaves in the body, and whether there is any early anti-tumor activity. It was for adults with advanced solid tumors that cannot be cured with surgery or standard treatments and that have measurable disease. The study aimed to learn about safety, pharmacokinetics, pharmacodynamics, and any early clinical benefit of the drug. Key exclusions included active infections, significant heart disease, untreated or progressing brain metastases, HIV or hepatitis B/C, prior anti-PD-L1 therapy, and recent systemic anticancer treatments.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests a combination of drug-eluting bead transcatheter arterial chemoembolization (DEB-TACE) with GEMOX chemotherapy, plus lenvatinib and pucotenlimab (a PD-1–targeting antibody), to treat unresectable intrahepatic cholangiocarcinoma and try to shrink tumors enough for surgery. - It is for adults whose cancer cannot currently be removed with surgery after multidisciplinary evaluation. - The study aims to assess the safety and feasibility of this combination and whether it can convert tumors to a resectable state. - Key exclusions include prior systemic therapy for this cancer, active infections or serious liver/heart disease, brain metastases, pregnancy, and uncontrolled HIV/HBV/HCV or other major health issues.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence is being studied. Conditions: Cholangiocarcinoma, Intrahepatic • Eligibility: Inclusion Criteria: * Post R0 resection, pathologically confirmed intrahepatic cholangiocarcinoma.Patients were also pathologically confirmed to have any of the following high-risk factors (ie, positive resection margins, positive lymph…. Goal: The purpose of the study is to observe the effect of PD-1 Antibody（Tislelizumab） Combined With Capecitabine as Adjuvant Therapy to Prevent the Recurrence in High-risk Patients With Cholangiocarcinoma After Curative Resection. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Fudan University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Profiling Program of Cancer Patients With Sequential Tumor and Liquid Biopsies (PLANET) is being studied. Conditions: Advanced / Metastic Solid Tumors, Glioblastoma, Chronic Leukemia Lymphocytic • Eligibility: Inclusion Criteria: I1. Adult male or female patient with confirmed diagnosis of advanced/metastatic cancer to be treated with standard anti-cancer treatment according to : * For metastatic Small…. Goal: The proposal is to conduct a prospective, multi-cohort study aiming to decipher molecular profiles/biological characteristics of advanced cancer patients during the course of their disease with longitudinal and sequential analyses of tumor and liquid biopsies. This approach will allow i) to develop a model in order to predict tumor response / resistance in real life conditions and to better understand adaptive mechanisms and ii) to potentially propose therapeutic options to enrolled patients following the review of the biological/molecular data generated during this study and during a Molecular Tumor Board in case of disease progression. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Centre Leon Berard.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests a new approach to reduce the time patients stay in the hospital after liver surgery by using a mix of objective clinical data, patient-reported factors, and other non-clinical information. - It is for adults undergoing elective liver surgery who agree to participate. - The study aims to learn whether this approach can improve safety of care and help control health-care costs in liver surgery. - Exclusions include emergency liver surgery and anyone who refuses to participate.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients is being studied. Conditions: Fruquintinib, Irinotecan, Capecitabine +1 • Eligibility: Inclusion Criteria: 1. Subjects voluntarily enrolled in the study and signed an informed consent form, were compliant and cooperated with follow-up visits; 2. Patients with metastatic colorectal adenocarcinoma…. Goal: This is a real-world observational study of fruquintinib in combination with irinotecan and capecitabine for the second-line treatment of patients with advanced colorectal cancer. Phase/Status/Sponsor: Unknown phase; UNKNOWN; China Medical University, China.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer is being studied. Conditions: Colorectal Cancer • Eligibility: Inclusion Criteria: 1. Written informed consent prior to performance of any study procedure. 2. Patient must be ≥18 years of age, at the time of signing the informed…. Goal: This is an open-label, multicenter, randomized study to be conducted in Chinese patients with RAS and BRAF wild-type mCRC. Patients who have already completed 9 cycles of standard first-line induction treatment, without discontinuation for toxicity, of cetuximab or fluorouracil or oxaliplatin,, and achieved disease control (including CR/PR and SD), and are progression free at the end of Cycle 9 will be assigned to 2 maintenance treatment groups by randomization in a 1:1 ratio to receive cetuximab + capecitabine (Arm A) or cetuximab alone (Arm B). Phase/Status/Sponsor: Unknown phase; UNKNOWN; Sun Yat-sen University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Risk of GAstric Adenocarcinoma After Cephalic Duodenopancreatectomy is being studied. Conditions: Cephalic Duodenopancreatectomy 10 or More Years Ago • Eligibility: 1. Inclusion Criteria: Criteria for inclusion for patient without endoscopy for research: * Patient living 10 years after a CPD performed for a benign or malignant condition in…. Goal: In view of the similarities of the surgical set-ups of partial gastrectomies and cephalic duodenopancreatectomies, and the increased risk of gastric cancer after early partial gastrectomy, it is possible that the former pancreatic cephalic duodenopancreatectomy pancreaticoduodenectomy (CPD) is also associated with the occurrence of stomach cancer. The investigators expect a high rate of cancer and high grade dysplasia in these patients based on literature data and available data on gastric cancer after partial gastrectomy. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Assistance Publique - Hôpitaux de Paris.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evaluation of MMR Status and PD-L1 Expression Using Specimens Obtained by EUS-FNB in Patients With Pancreatic Cancer is being studied. Conditions: Pancreatic Cancer • Eligibility: Inclusion Criteria * Age 18 to 90 years old * men or women * signed informed consent for EUS and EUS -FNB * the diagnosis of adenocarcinoma histologically…. Goal: Pancreatic ductal adenocarcinoma (PDAC) has a suboptimal response to standard therapies that modestly impact survival due to its ability to evade host immune surveillance. Emerging evidence has shown that the co-inhibitory receptors, such as programmed death 1 (PD-1), play a critical role in cancer immune-editing. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Ponderas Academic Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tests whether people with advanced solid tumors who have stable disease can stop PD-1/PD-L1 treatment after one year without harming outcomes. It is for patients being treated with PD-1/PD-L1 drugs (like pembrolizumab, nivolumab, atezolizumab, durvalumab, or avelumab). Participants are randomly assigned to stop treatment after about one year or continue treatment until the cancer progresses, to learn the best length of therapy. To join, patients must have at least stable disease on scans within six weeks of randomization; those with progressive disease before randomization or immune-related toxicity that prevents staying on therapy beyond one year are excluded.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types is being studied. Conditions: Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer +6 • Eligibility: Inclusion Criteria: * Subjects must have had at least one prior treatment with systemic therapy for advanced and unresectable, or metastatic disease OR is intolerant to, has refused…. Goal: Checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance, and the inhibition of this interaction is an effective treatment strategy for numerous malignancies. Phase/Status/Sponsor: Unknown phase; SUSPENDED; University of Florida.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 is being studied. Conditions: Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma +8 • Eligibility: Inclusion Criteria: INT230-6 monotherapy Cohorts EC2 and EC3, combination with KEYTRUDA® cohort DEC2 and combination with Yervoy cohort FEC. Where criteria diverge the DEC2 and FEC specific criteria…. Goal: This study evaluated the intratumoral administration of escalating doses of a novel, experimental drug, INT230-6. The study was conducted in patients with several types of refractory cancers including those at the surface of the skin (breast, squamous cell, head and neck) and tumors within the body such (pancreatic, colon, liver, lung, etc.). Phase/Status/Sponsor: Unknown phase; COMPLETED; Intensity Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Identification of New Diagnostic Protein Markers for Colorectal Cancer is being studied. Conditions: Colorectal Cancer • Eligibility: Inclusion Criteria: * Immunoassay for stool positive blood test or family screening * Patients seen in consultation for a colonoscopy * Patient who gave their consent for the…. Goal: The search for biochemical markers in patient's blood for non-invasive colorectal cancer diagnostic has not yielded satisfactory results to date. The search for blood in the stool by enzymatic techniques has certainly allowed the diminution of colorectal cancer mortality but its low sensitivity is still a disadvantage. Phase/Status/Sponsor: Unknown phase; COMPLETED; CHU de Reims.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma) is being studied. Conditions: Renal Cell Carcinoma • Eligibility: * All inclusion and exclusion criteria must be met and confirmed prior to enrollment. Unless specified, all laboratory normal ranges that are mentioned in inclusion and exclusion criteria…. Goal: Background: * GC1008 is a genetically engineered antibody designed to block the activity of transforming growth factor-beta (TGF-beta). Although TGF-beta has some normal and beneficial effects in the body, it is often over-produced in malignant melanoma tumors, and it can help the melanoma grow and spread. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Temozolomide in Treating Patients With Recurrent High-Grade Glioma is being studied. Conditions: Recurrent Central Nervous System Neoplasm • Eligibility: Inclusion Criteria * Patients with radiographically proven recurrent, intracranial malignant glioma will be eligible for this protocol. * All patients must sign an informed consent * Patients must…. Goal: RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well temozolomide works in treating patients with recurrent high-grade glioma. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of California, San Francisco.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer is being studied. Conditions: Renal Cell Carcinoma, Graft-Versus-Host Disease, Engraftment Syndrome • Eligibility: * INCLUSION CRITERIA: Recipient Diagnosis of metastatic renal cell carcinoma, either clear cell type or non-clear cell type. The diagnosis must be confirmed by the Laboratory of Pathology…. Goal: Background: Low-dose chemotherapy is easier for the body to tolerate than typical high-dose chemotherapy and involves a shorter period of complete immune suppression. Donor immune cells called lymphocytes, or T cells, fight residual tumor cells that might have remained in the recipients body after stem cell transplant, in what is called a graft-versus-tumor (GVT) effect. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy is being studied. Conditions: Islet Cell Carcinoma, Neuroendocrine Carcinoma, Neuroendocrine Tumor +1 • Eligibility: Inclusion criteria for both strata: * Advanced (unresectable or metastatic) biopsy-proven pancreatic Neuroendocrine tumor (NET) * Confirmed low-grade or intermediate-grade neuroendocrine carcinoma * Objective disease progression by Response…. Goal: The purpose of this study was to assess the efficacy and safety of everolimus in the treatment of advanced pancreatic neuroendocrine tumor (NET) not responsive to cytotoxic chemotherapy. All patients were treated with everolimus until either tumor progression was documented using a standard criteria that measures tumor size called Response Evaluation Criteria in Solid tumors (RECIST), or until unacceptable toxicity occurred, or until the patient or investigator requested discontinuation of treatment. Phase/Status/Sponsor: Unknown phase; COMPLETED; Novartis Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests LB4330, a fusion protein that targets Claudin 18.2 and activates CD8 T cells, to see if it is safe and tolerable in people with advanced solid tumors. - It is a first-in-human, open-label Phase I trial given by IV, with a dose-escalation part and a dose-expansion part. - Participants are adults aged 18-75 with advanced solid tumors; some cohorts require Claudin 18.2 expression while others do not, depending on the cohort. - The trial aims to learn about safety, tolerability, pharmacokinetics, and immunogenicity of LB4330. - Key exclusions include recent systemic cancer therapy, active infection, autoimmune disease, brain metastases needing steroids, and significant cardiovascular or liver/kidney problems.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This Phase II trial tests the combination of nivolumab and ipilimumab for people with rare cancers. Participants are grouped into three tumour streams: upper GI malignancies, neuroendocrine tumours, and rare gynecologic tumours. The study aims to see whether this immunotherapy combo can improve progression-free survival and overall survival, and to assess safety. Eligible adults must have confirmed disease in these groups and measurable disease, and must not have had prior combination PD-1/PD-L1 and CTLA-4 therapy; key exclusions include active brain metastases unless treated and stable, autoimmune disease, certain infections, pregnancy, and imprisonment.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma is being studied. Conditions: Advanced Solid Neoplasm, Aggressive Non-Hodgkin Lymphoma, Recurrent Solid Neoplasm +3 • Eligibility: Inclusion Criteria: * Patients must have a histologically documented (either primary or metastatic site) diagnosis of advanced solid tumor cancer (stage IV or unresectable) or aggressive lymphoma (diffuse…. Goal: The purpose of this research study is to determine the highest and safest dose of the experimental drug veliparib when combined with nivolumab. We will also study how safely this combination of medication can be given in advanced cancer and lymphoma and benefits of receiving this therapy. Phase/Status/Sponsor: Unknown phase; COMPLETED; Northwestern University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tested giving donor-derived natural killer (NK) cells (SMT-NK) together with pembrolizumab for advanced biliary tract cancer, including cholangiocarcinoma and gallbladder cancer. - It aimed to assess safety and look for signs that the combination could help control the cancer. - Eligible participants were adults with nonresectable or chemotherapy-refractory biliary tract cancer, with health criteria and possible inclusion of PD-L1 positive tumors or MSI-H/dMMR status. - Key exclusions include immune deficiency or autoimmune disease, active infection, prior anti-PD-1 therapy or prior NK cell therapy, pregnancy, and recent other cancers. - The trial is listed as completed.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable) is being studied. Conditions: Colorectal Cancer • Eligibility: Inclusion Criteria: * Histological or cytological confirmed advanced, metastatic, or progressive pMMR/MSS adenocarcinoma of colon or rectum * Participant must have progressed or be intolerant to prior systemic…. Goal: The purpose of this study is to learn if combination of the two drugs regorafenib and nivolumab is an effective treatment for pMMR - MSS colorectal cancer, a special type of cancer of the colon or rectum (pMMR stands for proficient Mismatch Repair; MSS stands for Microsatellite Stable) and whether it is safe for patients. Regorafenib works by blocking several different proteins involved in tumor growth. Phase/Status/Sponsor: Unknown phase; COMPLETED; Bayer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy is being studied. Conditions: Prostate Cancer Patients With Detectable PSA Following Prostatectomy • Eligibility: Inclusion Criteria: * \- Patient must have a history of prostatectomy (Open Radical or Robotic Assisted) with histopathologic documentation of adenocarcinoma of the prostate * Patient must have…. Goal: This is a Phase 1 dose escalation study of an investigational agent, everolimus, given in combination with standard radiation therapy, in prostate cancers with a rising PSA following a prostatectomy. A maximum of 33 people will be enrolled on this study at the University of Pennsylvania. Phase/Status/Sponsor: Unknown phase; COMPLETED; Abramson Cancer Center at Penn Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer is being studied. Conditions: Metastatic Colorectal Cancer • Eligibility: Inclusion Criteria: 1. Adult male and female subjects aged 18-80 years at screening visit 2. Pathologically confirmed diagnosis of MSS/pMMR colorectal adenocarcinoma 3. Presenting with metastatic disease: *…. Goal: Experimental immunotherapy in chemotherapy-refractory and immunotherapy-refractory metastatic colorectal cancer patients that have progressed, or are intolerant to, Longsurf (TAS-102) +/- Avastin (bevacizumab) or Stivarga (regorafenib) or Fruzaqla (fruquintinib) combining experimental AlloStim with an anti-programmed death ligand 1 (PD-L1) checkpoint inhibitor drug. Phase/Status/Sponsor: Unknown phase; WITHDRAWN; Mirror Biologics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies is being studied. Conditions: Gastrointestinal Cancer • Eligibility: Inclusion Criteria: 1. Histological or pathological confirmation of malignancy with a KRAS-activating mutation. 2. Extent of disease Advanced disease for which no curable options are available. Subjects who…. Goal: This research study is for patients with an advanced cancer that carries a mutation in a gene called KRAS. Genes are parts of our DNA which carry instructions for a cell (the smallest component of an body part). Phase/Status/Sponsor: Unknown phase; TERMINATED; Columbia University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tested the Serious Illness Conversation Guide (SICG), a scripted template to guide end-of-life discussions, in people with advanced gastrointestinal cancers. Eligible participants were adults with metastatic GI cancers whose disease had progressed after standard treatments, with some genetic exceptions (for example, patients with BRAF V600E mutations may enroll regardless of prior chemotherapy, and MSI-H tumors must have progressed after immunotherapy). The goal was to learn whether using SICG makes conversations about goals and end-of-life care more consistent and better documented, and whether it improves the quality of care and patients’ quality of life, along with provider opinions. The trial is terminated, and non-English-speaking patients were excluded.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer is being studied. Conditions: Colorectal Neoplasms • Eligibility: Inclusion Criteria * Histological confirmed previously treated colorectal cancer with adenocarcinoma histology with metastatic or recurrent unresectable disease at study entry. * Participants must have:. i) progressed during…. Goal: The purpose of this study is to evaluate relatlimab in combination with nivolumab, administered as a fixed-dose combination (nivolumab-relatlimab FDC, also referred to as BMS-986213) for the treatment of non-microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC) participants who failed at least 1 but no more than 4 prior lines of therapy for metastatic disease. Phase/Status/Sponsor: Unknown phase; TERMINATED; Bristol-Myers Squibb.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer is being studied. Conditions: Pancreatic Cancer • Eligibility: Inclusion Criteria: Inclusion Criteria: 1\. Part 1 Biopsy-proven metastatic pancreatic adenocarcinoma with documented radiographic disease progression on or after one or more systemic therapies. Chemotherapy given as part…. Goal: A prospective, open-label phase 2/3 trial in metastatic pancreatic cancer participants who have failed two lines of prior systemic therapy. The trial is designed to evaluate the safety and efficacy of SM-88 used with MPS (methoxsalen, phenytoin and sirolimus) in pancreatic cancer and will measure multiple endpoints, including overall survival, progression free survival, relevant biomarkers, quality of life, safety, and overall response rate. Phase/Status/Sponsor: Unknown phase; TERMINATED; Tyme, Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations is being studied. Conditions: Advanced Cholangiocarcinoma, FGFR2 Gene Mutation • Eligibility: Inclusion Criteria: * Histologically or cytologically confirmed unresectable locally advanced or metastatic cholangiocarcinoma. Participants with gallbladder cancer or ampulla of Vater carcinoma are not eligible * Have written…. Goal: Infigratinib is an oral drug which selectively binds to fibroblast growth factor receptor (FGFR) 2 and is being developed to treat participants with FGFR2 mutated cholangiocarcinoma. The purpose of the study is to evaluate the efficacy and safety of the investigational agent oral infigratinib vs standard of care chemotherapy (gemcitabine plus cisplatin) in first-line treatment of participants with unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion/rearrangement. Phase/Status/Sponsor: Unknown phase; TERMINATED; QED Therapeutics, a BridgeBio company.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer is being studied. Conditions: Metastatic Colorectal Cancer • Eligibility: Key inclusion criteria: 1. Patients with metastatic MSS colorectal adenocarcinoma.Note: MSI status will be performed locally by an immunohistochemistry (IHC) or PCR based test for eligibility. 2. Patients…. Goal: This was a phase Ib study of PDR001 in combination with bevacizumab and mFOLFOX6 as first line therapy in patients with metastatic microsatellite stable (MSS) colorectal cancer. The study was to have assessed primarily, the safety and tolerability and then the efficacy of PDR001 in combination with bevacizumab and mFOLFOX6. Phase/Status/Sponsor: Unknown phase; TERMINATED; Novartis Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers is being studied. Conditions: Anal Squamous Cell Carcinoma, Colorectal Neoplasms, Soft Tissue Sarcoma +5 • Eligibility: Inclusion Criteria: 1. Signed and dated PICF obtained prior to any trial-specific procedure that is not part of standard patient care. 2. Patient is ≥ 18 years-old at…. Goal: REFIT-MSS is a non-randomized, multicenter, open-label, multi-cohort, 2-stage, phase II trial to evaluate the efficacy and safety of regorafenib in combination with tislelizumab (referred as Rego-Tisle) in adult patients with select advance, previously treated, Mismatch Repair-Proficient/Microsatellite (pMMR/MSS) stable solid cancers. The multi-cohort design will allow for the examination of 8 separate cohorts of different cancers to determine whether further examination may be warranted in the individual indications. Phase/Status/Sponsor: Unknown phase; WITHDRAWN; Translational Research in Oncology.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors is being studied. Conditions: Gastrinoma, Glucagonoma, Insulinoma +3 • Eligibility: Inclusion Criteria: * Histologic diagnosis of a well- to moderately differentiated PNET (low-intermediate grade); NOTE: pathology report should state one of the following: low-grade, intermediate grade, moderately- or…. Goal: This phase II trial studies how well dovitinib lactate works in treating patients with pancreatic neuroendocrine tumors. Dovitinib lactate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; WITHDRAWN; Academic and Community Cancer Research United.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Impact of Methylation Alterations in Colon Cancer: Epidemiology and Prognosis is being studied. Conditions: Colon Cancer • Eligibility: Inclusion Criteria: * Adenocarcinomas of the colon (C18) and rectosigmoid junction (C19) * Resident in Côte-d'Or * Treated by surgical resection Exclusion Criteria: * Rectal cancer * Cancer…. Goal: We conducted a preliminary study in 2010 using the innovative Illumina GoldenGate (methylation assay) which has enabled us to characterize the level of methylation of 807 potential markers on a series of 200 adenocarcinomas of the colon (C18) and rectosigmoid junction (C19) resected between 1998 and 2001. The results, validated by pyrosequencing, allowed us to establish a panel of 12 markers to assess the level of methylation. Phase/Status/Sponsor: Unknown phase; WITHDRAWN; Centre Hospitalier Universitaire Dijon.

This summary may be inaccurate. Verify against ClinicalTrials.gov.